You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 297 No. 23, June 20, 2007 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA

Identifying Widely Covered Drugs and Drug Coverage Variation Among Medicare Part D Formularies

Chien-Wen Tseng, MD, MPH; Carol M. Mangione, MD, MSPH; Robert H. Brook, MD, ScD; Emmett Keeler, PhD; R. Adams Dudley, MD, MBA

JAMA. 2007;297:2596-2602.

Context  Clinicians can find it difficult to know which drugs are covered for their Medicare patients because formularies vary widely among Medicare Part D plans and many states have 50 or more such plans.

Objective  To determine whether Part D formularies in California (the state with the most Medicare beneficiaries) and Hawaii have at least 1 drug within each of 8 treatment classes for hypertension, hyperlipidemia, and depression that can be identified for clinicians as "widely covered" by the vast majority of Part D plans.

Design and Setting  Use of the medicare.gov Web site (March 1-April 15, 2006) to examine 72 California and 43 Hawaii Part D formularies' coverage of 8 treatment classes (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, calcium channel blockers, loop diuretics, selective serotonin reuptake inhibitors, statins, and thiazide diuretics), with evaluation of how often drugs were widely covered (defined as inclusion in ≥90% of formularies at co-payments of ≤$35 without prior authorization).

Main Outcome Measure  Identification of treatment classes with at least 1 widely covered drug.

Results  For California, coverage for the 75 drugs examined ranged from 7% to 100%. Despite this variation, 7 of 8 classes (excluding angiotensin II receptor blockers) had at least 1 widely covered drug. Of the 34 widely covered drugs (45%), all but 2 were generic. Restricting widely covered to include 95% or more of formularies at co-payments of $15 or less still resulted in 7 of 8 classes with at least 1 widely covered drug. Overall, 73% of generic drugs and 6% of brand-name drugs were widely covered. Findings were similar for Hawaii.

Conclusions  Formularies varied substantially; however, all but 1 treatment class examined had 1 or more widely covered drugs at low co-payments. Knowing which drugs are widely covered would assist clinicians in prescribing, since not all generic drugs were widely covered. Clinicians should know that few brand-name drugs are widely covered and check coverage before prescribing.


Author Affiliations: Department of Family Medicine and Community Health, John A. Burns School of Medicine at University of Hawaii, Honolulu (Dr Tseng); Pacific Health Research Institute, Honolulu (Dr Tseng); RAND Corporation, Santa Monica, Calif (Drs Mangione, Brook, and Keeler); Department of Medicine, David Geffen School of Medicine at UCLA and Department of Health Services, UCLA School of Public Health, Los Angeles, Calif (Drs Mangione and Brook); and Department of Medicine and Institute for Health Policy Studies, University of California, San Francisco (Dr Dudley).







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.